Monitoring of voriconazole plasma concentrations in immunocompromised paediatric patients
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Monitoring of voriconazole plasma concentrations in immunocompromised paediatric patients
Authors
Keywords
-
Journal
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
Volume 67, Issue 11, Pages 2717-2724
Publisher
Oxford University Press (OUP)
Online
2012-07-14
DOI
10.1093/jac/dks258
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Comparison of Pharmacokinetics and Safety of Voriconazole Intravenous-to-Oral Switch in Immunocompromised Children and Healthy Adults
- (2011) Timothy A. Driscoll et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Comparison of Pharmacokinetics and Safety of Voriconazole Intravenous-to-Oral Switch in Immunocompromised Adolescents and Healthy Adults
- (2011) Timothy A. Driscoll et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Observational Study of the Clinical Efficacy of Voriconazole and Its Relationship to Plasma Concentrations in Patients
- (2011) Peter F. Troke et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Voriconazole as primary antifungal prophylaxis in children undergoing allo-SCT
- (2011) J R Molina et al. BONE MARROW TRANSPLANTATION
- Voriconazole drug monitoring in the management of invasive fungal infection in immunocompromised children: a prospective study
- (2011) P. Soler-Palacin et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Therapeutic Drug Monitoring of Voriconazole After Intravenous Administration in Infants and Children With Primary Immunodeficiency
- (2011) Magdalena Gerin et al. THERAPEUTIC DRUG MONITORING
- Voriconazole Pharmacokinetics and Safety in Immunocompromised Children Compared to Adult Patients
- (2010) C. Michael et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Pharmacokinetics, Safety, and Tolerability of Voriconazole in Immunocompromised Children
- (2010) T. J. Walsh et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Serial Plasma Voriconazole Concentrations after Allogeneic Hematopoietic Stem Cell Transplantation
- (2009) S. M. Trifilio et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Voriconazole Pharmacokinetics and Pharmacodynamics in Children
- (2009) Michael Neely et al. CLINICAL INFECTIOUS DISEASES
- Monitoring trough concentration of voriconazole is important to ensure successful antifungal therapy and to avoid hepatic damage in patients with hematological disorders
- (2009) Koki Ueda et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- Safety, tolerance and outcome of treatment with liposomal amphotericin B in paediatric patients with cancer or undergoing haematopoietic stem cell transplantation
- (2009) Hedwig Kolve et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Population Pharmacokinetic Analysis of Voriconazole Plasma Concentration Data from Pediatric Studies
- (2008) M. O. Karlsson et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Hallucinations during Voriconazole Therapy
- (2008) Dimitrios I. Zonios et al. CLINICAL INFECTIOUS DISEASES
- Defining Responses to Therapy and Study Outcomes in Clinical Trials of Invasive Fungal Diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer Consensus Criteria
- (2008) Brahm H. Segal et al. CLINICAL INFECTIOUS DISEASES
- Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group
- (2008) Ben De Pauw et al. CLINICAL INFECTIOUS DISEASES
- Voriconazole Therapeutic Drug Monitoring in Patients with Invasive Mycoses Improves Efficacy and Safety Outcomes
- (2007) A. Pascual et al. CLINICAL INFECTIOUS DISEASES
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More